Follow
'A similar percentage of deaths from the same side effect followed in the clinical trial of Leqembi, an F.D.A.-approved Alzheimer’s drug from the company Eisai. A third drug, Aduhelm, was also approved by the F.D.A., but is rarely used because of concerns about its effectiveness and its high price. Brain swelling was reported in its clinical trial and deaths were reported in patients taking Aduhelm after it was approved.'
https://www.nytimes.com/2023/05/03/health/alzheimers-drug-eli-lilly-trial.html
@cyrilpedia
Those plaques soak up activated fluid phase membrane attack complexes. Without them, the fMACs are going to inflict bystander damage on host tissue--swelling, shrinkage, and bleeding.
CA is most likely induced by HSV-1, but there's no reason other pathogens can't do the same. AD and other Complement dependent neuro diseases typically occur well past mean reproductive age, so there's little selective pressure to refine the mechanisms involved.
#ComplementNeoantigen
#AmyloidBeta